Asia Pacific Biomarker Testing Services Market Size, Share, and COVID-19 Impact Analysis, By Service (Biomarker Assay Development & Validation, Flow Cytometry, and Others), By Application (Oncology, Drug Discovery & Development, and Others), and Asia Pacific Biomarker Testing Services Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Biomarker Testing Services Market Insights Forecasts to 2035

• The Asia Pacific Biomarker Testing Services Market Size was Estimated at USD 96.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.94% from 2025 to 2035
• The Asia Pacific Biomarker Testing Services Market Size is Expected to Reach USD 247.5 Million by 2035

According to a Research Report published by Spherical Insights & Consulting, the Asia Pacific Biomarker Testing Services Market Size is Anticipated to reach USD 247.5 Million by 2035, Growing at a CAGR of 8.94% from 2025 to 2035. The rising need for personalized medicine and the use of biomarkers in drug development & clinical trials are driving the biomarker testing services market in the Asia Pacific region.

Market Overview

The Asia Pacific biomarker testing services market refers to the industry offering services for analyzing objective measures (biomarkers) to diagnose, monitor, and predict disease, especially for personalized medicine and drug development. Biomarker testing is the laboratory method in which samples of tissue, blood, or other body fluids are used to check for certain genes, proteins, or other molecules that may be a sign of cancer. It is a critical tool in drug discovery and development. Integration of cancer biomarkers into oncology is revolutionizing cancer treatment by advancing cancer therapeutics and the prognosis of cancer patients, as the use of biomarkers enables tailored treatment that is based on the unique molecular profile of a patient’s tumor. Further, strategic collaborations between pharmaceutical companies and diagnostic laboratories are revolutionizing research practices and driving innovation. The rising demand for targeted diagnostics by companies is creating opportunities for biomarker-driven solutions, which are anticipated to promote the market for biomarker testing services.

Report Coverage

This research report categorizes the market for the Asia Pacific biomarker testing services market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific biomarker testing services market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific biomarker testing services market.

Driving Factors

With the increasing development of genomics & proteomics and rising focus on customized healthcare, the development of personalized treatment and diagnostics methods is driving the market. In drug development, biomarkers aid in identifying the patient population, predicting treatment responses, and monitoring disease progression. Biomarker testing aids in identifying genes, proteins, and other substances, which are called tumor markers, providing cancer information that helps healthcare providers to choose cancer treatment for the patient. It was estimated that there were nearly 20 million new cases of cancer in the year 2022, alongside 9.7 million deaths from cancer. The concern regarding the increased cases of cancer is anticipated to drive the market demand for biomarker testing services.

Restraining Factors

The increased cost of biomarker-based diagnostics and restricted reimbursement policies are restraining the biomarker testing services market. Further, the regulatory and standardization issues related to biomarker testing services are challenging the market growth.

Market Segmentation

The Asia Pacific biomarker testing services market share is classified into service and application.

• The biomarker assay development & validation segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific biomarker testing services market is segmented by service into biomarker assay development & validation, flow cytometry, and others. Among these, the biomarker assay development & validation segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Biomarker assay development & validation include the development for creating an assay for a specific molecule (protein, nucleic acid, etc.) and the establishment of the assay’s performance and reliability for its intended use. Assay development and validation are required for approval or clearance for biomarker-based diagnostics and therapies to meet the strict regulatory standards.

• The oncology segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific biomarker testing services market is segmented by application into oncology, drug discovery & development, and others. Among these, the oncology segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Biomarker testing services help oncologists select the most effective targeted therapies and immunotherapy, with minimal side effects and improved outcomes. The growing cancer prevalence rate, along with an increasing targeted therapies demand is contributing to driving the market in the oncology segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific biomarker testing services market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pharmaron
• WuXiAppTec
• Thermo Fisher Scientific (PPD)
• ICON Plc
• IQVIA
• Eurofins Scientific
• SGS SA
• Charles River Laboratories
• Labcorp Drug Development
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Biomarker Testing Services Market based on the below-mentioned segments:

Asia Pacific Biomarker Testing Services Market, By Service

• Biomarker Assay Development & Validation
• Flow Cytometry
• Others

Asia Pacific Biomarker Testing Services Market, By Application

• Oncology
• Drug Discovery & Development
• Others